Porton Biopharma Digital Brochure - page 3

Erwinase
PBL is the sole manufacturer of Erwinase which is indicated for the
treatment of Acute Lymphoblastic Leukaemia (ALL), the most common
form of cancer in children.
The product is produced in our licensed pharmaceutical manufacturing
facilities. Since its first registration in the UK in 1985 Erwinase has to
date been registered in 20 countries and commercialised in up to 80
countries world-wide, including approval in the USA by the FDA in
November 2011 under the name Erwinaze.
Erwinase is an L-asparaginase enzyme derived from the bacterium
Erwinia chrysanthemi
that is used as part of the treatment protocols
in conjunction with radiotherapy or chemotherapy. Erwinase is used
when patients demonstrate an allergic reaction to L-asparaginase
enzymes from other sources.
In those aged 14 or younger, more than 90% will survive their leukaemia
for 5 years or more after they are diagnosed*.
*Cancer Research UK
®
®
®
®
®
®
1,2 4,5,6,7,8
Powered by FlippingBook